비허혈성 심근병증에서 심장돌연사의 일차적 예방을 위한 삽입형 제세동기
Implantable Cardioverter-defibrillator for Primary Prevention of Sudden Cardiac Death in Non-ischemic Cardiomyopathy
2
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
The insertion of implantable cardioverter-defibrillators (ICD) in patients with non-ischemic cardiomyopathy (NICM) has been recommended by recent guidelines. However, current evidence shows limited benefits to inserting ICDs in patients with NICM. Recently, the defibrillator implantation in patients with non-ischemic systolic heart failure (DANISH) trial, a large randomized trial of more than 1,100 patients with NICM, was conducted to compare the primary prevention of all-cause mortality between optimal medical therapy, cardiac resynchronization therapy, and ICD implantation. The DANISH trial revealed no differences in all-cause mortality between the groups after 5 years. However, in patients younger than 68 years of age, the rate of death from any cause was significantly lower in the ICD group compared to the control group. In addition, the rate of sudden cardiac death was lower in the ICD group compared to the control group in patients under 68 years. The results of DANISH will likely change guidelines about the insertion of ICD in patients with NICM, and encourage the use of ICD in patients with NICM.
Abstract
The insertion of implantable cardioverter-defibrillators (ICD) in patients with non-ischemic cardiomyopathy (NICM) has been recommended by recent guidelines. However, current evidence shows limited benefits to inserting ICDs in patients with NICM. Recently, the defibrillator implantation in patients with non-ischemic systolic heart failure (DANISH) trial, a large randomized trial of more than 1,100 patients with NICM, was conducted to compare the primary prevention of all-cause mortality between optimal medical therapy, cardiac resynchronization therapy, and ICD implantation. The DANISH trial revealed no differences in all-cause mortality between the groups after 5 years. However, in patients younger than 68 years of age, the rate of death from any cause was significantly lower in the ICD group compared to the control group. In addition, the rate of sudden cardiac death was lower in the ICD group compared to the control group in patients under 68 years. The results of DANISH will likely change guidelines about the insertion of ICD in patients with NICM, and encourage the use of ICD in patients with NICM.
참고문헌 (17)
- Connolly SJ, "Meta-analysis of the implantable cardioverter defibrillator secondary prevention trials. AVID, CASH and CIDS studies. Antiarrhythmics vs Implantable Defibrillator study. Cardiac Arrest Study Hamburg. Canadian Implantable Defibrillator Study", Eur Heart J, 21, pp.2071~2078 (2000)
- Ponikowski P, "2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC", Eur J Heart Fail, 18, pp.891~975 (2016)
- Yancy CW, "2013 ACCF", AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation, J Am Coll Cardiol, pp.2013, 62[DOI]
- Bristow MR, "Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure", N Engl J Med, 350, pp.2140~2150 (2004)
- Bardy GH, "Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure", N Engl J Med, 352, pp.225~237 (2005)
- Desai AS, "Implantable defibrillators for the prevention of mortality in patients with nonischemic cardiomyopathy: a meta-analysis of randomized controlled trials", JAMA, 292, pp.2874~2879 (2004)
- KSHF guideline for the management of chronic heart failure 2016, "The Korean Society of hear Failure", The Korean Society of hear Failure, ~ (2016)
- Curtis JP, "Association of physician certification and outcomes among patients receiving an implantable cardioverter-defibrillator", JAMA, 301, pp.1661~1670 (2009)
- Køber L, "Defibrillator implantation in patients with nonischemic systolic heart failure", N Engl J Med, 375, pp.1221~1230 (2016)
- Zipes DP, "ACC", AHA, American Heart Association task force and the European Society of Cardiology Committee for practice guidelines (writing Committee to Develop Guidelines for Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death) developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society, pp.Eur Heart J, 2006[DOI]
- Luu M, "Diverse mechanisms of unexpected cardiac arrest in advanced heart failure", Circulation, 80, pp.1675~1680 (1989)
- Klein L, "Sudden cardiac death in heart failure", Cardiol Clin, 32, pp.135~144 (2014)
- Pogwizd SM, "Reentrant and focal mechanisms underlying ventricular tachycardia in the human heart", Circulation, 86, pp.1872~1887 (1992)
- Bansch D, "Primary prevention of sudden cardiac death in idiopathic dilated cardiomyopathy:the Cardiomyopathy Trial (CAT)", Circulation, 105, pp.1453~1458 (2002)
- Strickberger SA, "Amiodarone versus implantable cardioverter-defibrillator:randomized trial in patients with nonischemic dilated cardiomyopathy and asymptomatic nonsustained ventricular tachycardia--AMIOVIRT", J Am Coll Cardiol, 41, pp.1707~1712 (2003)
- Kadish A, "Prophylactic defibrillator implantation in patients with nonischemic dilated cardiomyopathy", N Engl J Med, 350, pp.2151~2158 (2004)
- McMurray JJ, "The ICD in heart failure - time for a rethink?", N Engl J Med, 375, pp.1283~1284 (2016)